In Silico Insight
A report shows the benefits of synthetic data for clinical trials
A report published by Accenture and Phesi shows that synthetic data can help drive faster, more efficient clinical trials. According to the document, AI systems that analyze electronic medical records and track patient outcomes allow for new data on trial protocols and results to be generated easily. However, the collaborators also point out that there are barriers to implementation. Often, pharma companies do not have access to data from varied sources and can also refuse to share the data they generate with others, preventing accurate statistical analysis.
“Once the availability of data is addressed, an investment into technology, skills, and leadership is a must,” the report states. “Pharma companies need to do more to identify and adopt advanced technologies to work with the data needed for in-silico clinical trials. R&D leaders will have to be bold in defining their next steps.”
Read the full report at https://accntu.re/31u91HX
After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!
